國家衛生研究院 NHRI:Item 3990099045/10126
English  |  正體中文  |  简体中文  |  全文笔数/总笔数 : 12145/12927 (94%)
造访人次 : 855295      在线人数 : 1050
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜寻范围 查询小技巧：
  • 您可在西文检索词汇前后加上"双引号"，以获取较精准的检索结果
  • 若欲以作者姓名搜寻，建议至进阶搜寻限定作者字段，可获得较完整数据
    •  进阶搜寻
    主页 ‧ 登入 ‧ 上传 ‧ 说明 ‧ 关于NHRI ‧ 管理 到手机版


    jsp.display-item.identifier=請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/10126


    题名: Glucocorticoids may compromise the effect of gefitinib in non-small cell lung cancer
    作者: Wang, HY;Chang, YL;Cheng, CC;Chao, MW;Lin, SI;Pan, SL;Hsu, CC;Liu, TW;Cheng, HC;Tseng, CP;Liu, SJ;Tsai, HJ;Chang, HY;Hsu, JT
    贡献者: Institute of Biotechnology and Pharmaceutical Research;Division of Health Services and Preventive Medicine;Division of Vaccine Research and Development;National Institute of Cancer Research;Division of Biostatistics and Bioinformatics
    摘要: The epidermal growth factor receptor (EGFR)-targeting tyrosine kinase inhibitors (TKIs) have shown remarkable benefits in non-small cell lung cancer (NSCLC) patients with drug-sensitive mutations in the EGFR gene. Responsive patients are usually continuously prescribed with TKIs until disease progression. Glucocorticoids (GCs) are potent homeostasis maintaining drugs and are frequently used in cancer patients to alleviate discomforts caused by anti-cancer therapies. Several previous studies reported that concomitant use of GCs may compromise the efficacy of chemo-therapeutics in patients with solid tumors. Little is known in the concomitant use of target therapy with GCs in treating NSCLC. In this study, we hypothesized that concomitant use of GCs in EGFR-TKI therapy may be detrimental and addressed this issue using cell cultures and xenograft studies followed by a retrospective population study based on data from the Taiwan national health insurance system. In cell cultures and xenograft studies, GCs were shown to unequally compromise the anti-cancer efficacy of TKIs in both PC9 and NCI-H1975 NSCLC cells models. In the retrospective population study, patients with similar disease status that were co-medicated with GCs had a significantly higher risk of disease progression.
    日期: 2016-12
    關聯: Oncotarget. 2016 Dec;7(52):85917-85928.
    Link to: http://dx.doi.org/10.18632/oncotarget.13185
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000391422500022
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85007492453
    显示于类别:[徐祖安] 期刊論文
    [張新儀] 期刊論文
    [許志成] 期刊論文
    [劉士任] 期刊論文
    [劉滄梧] 期刊論文
    [蔡慧如] 期刊論文

    文件中的档案:

    档案 描述 大小格式浏览次数
    PUB27835586.pdf2508KbAdobe PDF530检视/开启


    在NHRI中所有的数据项都受到原著作权保护.

    TAIR相关文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回馈